Table 2. Ongoing large scale randomized clinical trials with Y90-radioembolization in hepatocellular carcinoma.
| Acronym | NCT ID | Phase | Countries | N | Endpoint | Experimental Arm | Comparator | Estimated Completion Date | Status |
|---|---|---|---|---|---|---|---|---|---|
| PREMIERE | 00956930 | II | USA | 124 | TTP | Y90 | cTACE | Aug 2018 | Recruiting |
| SIRveNIB | 01135056 | III | Asia-Pacific | 360 | Survival | Y90 | Sorafenib | Jul 2015 | Recruiting |
| SARAH | 01482442 | III | France | 400 | Survival | Y90 | Sorafenib | Mar 2015 | Recruiting |
| STOP | 01556490 | III | USA-Europe | 400 | Survival | Y90 + Sorafenib | Sorafenib | Oct 2016 | Recruiting |
| SORAMIC | 01126645 | III | Europe | 375 | Survival | Y90 + Sorafenib | Sorafenib | Feb 2014 | Recruiting |
| YES-p | pending | III | Europe, Asia, USA | 328 | Survival | Y90 | Sorafenib | - | Initiated |